Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024: Widening Research Purview - From Cancer to Autoimmune Disorders [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
The landscape of VISTA-targeted therapeutics is characterized by active research, early-stage clinical development, and growing interest from both the scientific community and the pharmaceutical sector. As research progresses, VISTA inhibitors emerge as a beacon of innovation, holding up hope not only for cancer treatments but also for viral infections, autoimmune illnesses, and other ailments. At present, cancer, mainly solid tumors, are dominating the research and development landscape of VISTA-targeted therapies. However, ongoing research has also associated the functions of VISTA with autoimmune and inflammatory disorders, wherein aberrant immune system activation damages tissue. This can however, with averted with the use of VISTA agonists, which can help expand the potential of VISTA as a therapeutic target to diseases mediated by the immune system. Additionally, modulation of VISTA activity has also been linked to viral infection through research findings indicating the VIST
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- India Generic Drugs Market Research 2024: Demand for Accessible and Cost-effective Solutions Bolsters Growth - Competition, Forecasts and Opportunities to 2030 [Yahoo! Finance]Yahoo! Finance
- Generic Drugs Market Report 2024-2034: Patent Expiration of Blockbuster Drugs in this Decade and Growth of Biologics and Biosimilars Fueling Opportunities [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare BusinessBusiness Wire
- Haleon to sell overseas nicotine therapy business to Dr. Reddy's [Seeking Alpha]Seeking Alpha
RDY
Earnings
- 5/8/24 - Beat
RDY
Sec Filings
- 7/5/24 - Form 6-K
- 7/3/24 - Form 6-K
- 7/3/24 - Form 6-K
- RDY's page on the SEC website